Biomarkers for local recurrence after breast-conservation - A nested case-control study

Breast Cancer Research and Treatment

Volumn 57, Issue 3, 1999, Pages 245-259

  Dalberg, K ^a   Eriksson, E ^a   Kanter, L ^a   Sandelin, K ^a   Liedberg, A ^a   Auer, G ^a   Thorstensson, S ^b   Fredriksson, I ^c   Johansson, U ^a   Rutqvist, L E ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KALMAR COUNTY HOSPITAL   (Sweden)

^c STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

Biological markers; Breast cancer; Ipsilateral breast tumor recurrences; Prognosis

Indexed keywords

BIOLOGICAL MARKER; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGE; AGED; ANGIOGENESIS; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER RECURRENCE; CASE CONTROL STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE C ERB; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; AGE FACTORS; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HUMANS; LYMPHATIC METASTASIS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 0032761212     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006281718793     Document Type: Article

References (75)

1. 1. Blichert-Toft M, Rose C, Andersen JA, et al.: Danish randomised trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. J Natl Cancer Inst Monograph 11: 19-25, 1992
2. 2. Fisher B, Redmond C, Wolmark N, et al.: Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with or without irradiation in the treatment of breast cancer. New Engl J Med 333: 1456-1461, 1995
3. 3. Sarrazin D, Le MG, Arriagada R, et al.: Ten year results of a randomised trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol 14: 177-184, 1989
4. 4. van Dongen JA, Bartelink H, Fentiman IS, et al.: Factors influencing local relapse and survival and results of salvage treatment after breast-conserving therapy in operable breast cancer: EORTC trial 10801, breast conservation compared with mastectomy in TNM stage I and II breast cancer. Eur J Cancer 28A(4/5): 801-805, 1992
5. 5. Veronesi U, Banfi A, Salvadori B, et al.: Breast conservation is the treatment of choice in small breast cancer: Long-term results of a randomized trial. Eur J Cancer 26(6): 668-670, 1990
6. 6. Fisher B, Redmond C, Poisson R, et al.: Eight year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. New Engl J Med 320(13): 822-828, 1989
7. 7. Clark RM, McCullogh PB, Levine MN, et al.: Randomized clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer. J Natl Cancer Inst 84: 683-689, 1992
8. 8. Veronesi U, Luini A, Del Vecchio M, et al.: Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. New Engl J Med 328(22): 1587-1591, 1993
9. 9. Liljegren G, Holmberg L, Adami HO: Sector resection with or without postoperative radiotherapy for stage I breast cancer: five-year results of a randomized trial. J Natl Cancer Inst 86: 717-722, 1994
10. 10. Fisher B, Costantino J, Redmond C, et al.: A randomized clinical trial evaluating Tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. New Engl J Med 320(8): 479-484, 1989
11. 11. Fisher B, Redmond C, Dimitrov NV, et al.: A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. New Engl J Med 320(8): 473-478, 1989
12. 12. Dalberg K, Johansson H, Johansson U, Rutqvist LE: Randomized trial of long-term adjuvant tamoxifen plus postoperative radiation therapy versus radiation therapy alone for patients with early stage breast carcinoma treated with breast-conserving surgery. Cancer 82: 2204-2211, 1998
13. 13. Borger J, Kemperman H, Hart A, et al.: Risk factors in breast-conservation therapy. J Clin Oncol 12(4): 653-660, 1994
14. 14. Stotter A, Atkinson EN, Fairston BA, McNeese M, Oswald MJ, Balch CM: Survival following locoregional recurrence after breast conservation therapy for cancer. Ann Surg 212(2): 166-172, 1990
15. 15. de La Rochofordiere A, Asselain B, Campana F, et al.: Age as prognostic factor in premenopausal breast carcinoma. The Lancet 341: 1039-1042, 1993
16. 16. Boyages J, Recht A, Connolly JL, et al.: Early breast cancer: predictors of breast recurrence for patients treated with conservative surgery and radiation therapy. Radiother Oncol 19: 29-41, 1990
17. 17. Kurtz JM: Factors influencing the risk of local recurrence in the breast. Eur J Cancer 28(2/3): 660-666, 1992
18. 18. Kurtz JM, Jacquemier J, Amalric R, et al.: Risk factors for breast recurrence in premenopausal and postmenopausal patients with ductal cancers treated by conservation therapy. Cancer 65: 1867-1878, 1990
19. 19. Recht A, Connolly JL, Schnitt SJ, et al.: The effect of young age on tumor recurrence in the treated breast after conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys 14: 3-10, 1988
20. 20. Haffty BG, Fischer D, Rose M, et al.: Prognostic factors for local recurrence in the conservatively treated breast cancer patient: a cautious interpretation of the data. J Clin Oncol 9(6): 997-1003, 1991
21. 21. Bartelink H, Borger JH, van Dongen JA, Peterse JL: The impact of tumor size and histology on local control after breast-conserving therapy. Radiother Oncol 11: 297-303, 1988
22. 22. Vicini PA, Recht A, Abner A, et al.: Recurrence in the breast following conservative surgery and radiation therapy for early-stage breast cancer. J Natl Cancer Inst Monographs 11: 33-39, 1992
23. 23. Pezner RD, Wagman LD, Ben-Ezra J, Odom-Maryon T: Breast conservation therapy: local tumor control in patients with pathologically clear margins who receive 5000 cGy breast irradiation without local boost. Breast Cancer Res Treat 32: 261-267, 1994
24. 24. Ghossein NA, Alpert S, Barba J, et al.: Breast Cancer. Importance of adequate surgical excision prior to radiotherapy in the local control of breast cancer in patients treated conservatively. Arch Surgery 127: 411-415, 1992
25. 25. Marx J: How cells cycle toward cancer. Science 263: 319-321, 1994
26. 26. Hunter T: Braking the Cycle. Cell 75: 839-841, 1993
27. 27. Stinchomb D: Constaining the cell cycle: Regulation cell division and differentiation by gene therapy. Nature Med 1: 1004-1006, 1995
28. 28. Sporn M, Roberts A: Peptide growth factors and inflammation, tissue repair, and cancer. J Clin Invest 78: 329-332, 1986
29. 29. Gullick WJ: Expression of the c-erbB-2 proto-oncogene protein in human breast cancer. Recent Results Cancer Res 113: 51-56, 1989
30. 30. Norberg T, Jansson T, Sjögren S, et al.: Overview on human breast cancer with focus on prognostic and predictive factors with special attention on the tumour suppressor gene p53. Acta Oncol 5: 96-102, 1996
31. 31. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990
32. 32. Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. New Engl J Med 324: 1-8, 1991
33. 33. Bouxubar N, Walker KJ, Griffiths K, et al.: Ki67 immunostaining in primary breast cancer: Pathological and clinical assosiations. Br J Cancer 59: 943-947, 1989
34. 34. Veronesi S, Maisano C, Scibilia J: Comparative prognostic value of Ki-67 and MIB-1 proliferation indices in breast cancer. Anticancer Res 16: 2717-2722, 1996
35. 35. Auer GU, Caspersson TO, Wallgren AS: DNA content and survival in mammary carcinoma. Analyt Quant Cytol 2: 161-165, 1980
36. 36. Fallenius A, Auer C, Carstensen J: Prognostic significance of DNA measurements in 409 consecutive breast cancer patients. Cancer 62: 331-341, 1988
37. 37. Howell A, Barnes D, Harland R, et al.: Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet i: 588-591, 1984
38. 38. Nomura Y, Miura S, Koyama H, et al.: Relative effect of steroid hormone receptors on the prognosis of patients with operable breast cancer. Cancer 69: 153-164, 1992
39. 39. Pezzella F, Gatter K: What is the value of bcl-2 protein detection for histopathologists? Histopathology 26: 89-93, 1995
40. 40. Davidoff AM, Herndon JE, Glover NS, et al.: Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery 110: 259-264, 1991
41. 41. Elledge RM, Fuqua AW, Clark GM, et al.: The role and prognostic significance of p53 gene alterations in breast cancer. Breast Cancer Res Treat 27: 95-102, 1993
42. 42. Isola J, Visakorpi T, Holli K, Kallioniemi O-P: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84(14): 1109-1114, 1992
43. 43. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 351: 453-456, 1991
44. 44. Folkman J, Watson K, Ingeber D, Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58-61, 1989
45. 45. Dalberg K, Mattsson A, Rutqvist LE, et al.: Breast conserving surgery for invasive breast cancer: Risk factors for ipsilateral breast tumor recurrences. Breast Cancer Res Treat 43: 73-86, 1997
46. 46. World Health Organisation: Histological Typing of Breast Tunours. 2nd edition. Geneva, 1981.
47. 47. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410, 1991
48. 48. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11: 359-377, 1957
49. 49. Wrange Ö, Nordenskjöld B, Gustafsson JÅ: Cytosol estradiol receptor in human mammary carcinoma: an assay based on isoelectric focusing in polyacrylamide gel. Anal Biochem 85(2): 461-475, 1978
50. 50. Wrange Ö, Humla S, Ramberg I, et al.: Progestin-receptor analysis in human breast cancer cytosol by isoelectric focusing in slabs of polyacrylamide gel. J Ster Biochem 14: 141-148, 1981
51. 51. Rutqvist LE, Cedermark B, Glas U, et al.: The Stockholm trial on adjuvant tamoxifen in early breast cancer. Correlation between estrogen receptor level and treatment effect. Breast Cancer Res Treat 10: 255-266, 1987
52. 52. Breslow NE, Day NE: Statistical Methods in Cancer Research. Vol. I. The analysis of case-control studies. International Agency for Research on Cancer, Lyon, 1980
53. 53. Clayton D, Hills M: Statistical Models in Epidemiology. Oxford Science Publications, Oxford University Press, 1993
54. 54. Liljegren G, Lindgren A, Bergh J, et al.: Risk factors for local recurrence after conservative treatment in stage I cancer. Definition of a subgroup not requiring radiotherapy. Ann Oncol 8: 235-241, 1997
55. 55. Tabar L, Fagerberg G, Duffy SW, Day NE, Gad A, Gröntoft O: Update of the Swedish two-county program of mammographic screening for breast cancer. Radiol Clin North Am 30: 187-210, 1992
56. 56. Nyström L, Rutqvist LE, Wall S, et al.: Breast cancer screening with mammography; overview of Swedish randomised trials. Lancet 341: 973-978, 1993
57. 57. Gyenes G, Gagliardi G, Lax I, et at.: Evaluation of irradiated heart volumes in Stage I breast cancer patients treated with postoperative adjuvant radiotherapy. J Clin Oncol 15: 1348-1353, 1997
58. 58. Cuzick J, Stewart H, Rutqvist LE, et al.: Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 12: 447-453, 1994
59. 59. Rutqvist LE, Lax I, Fornander T, Johansson H: Cardiovascular mortality in a randomized trial of adjuvant radiation therapy versus surgery alone in primary breast cancer. Int J Radiat Oncol Biol Phys 22: 887-896, 1992
60. 60. Rutqvist LE, Liedberg A, Hammar N, Dalberg K: Myocardial infarction among women with early-stage breast cancer treated with conservative surgery and breastirradiation. Int J Radiat Oncol Biol Phys, 1998 (in press)
61. 61. Kattlove H, Liberati A, Keeler E, et al.: Benefits and costs of screening and treatment for early breast cancer. JAMA 11(2): 142-154, 1995
62. 62. Liljegren G, Karlsson G, Bergh J, Holmberg L: The cost-effectiveness of routine postoperative radiotherapy after sector resection and axillary dissection for breast cancer stage I. Results from a randomized trial. Ann Oncol 8(8): 757-763, 1997
63. 63. Forrest P, Stewart H, Everington D, et al.: Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Lancet 348: 708-713, 1996
64. 64. Silvestrini R, Daidone M, Di Fronzo G: Relationship between proliferative activity and estrogen receptors in breast cancer. Cancer 44: 665-670, 1979
65. 65. Meyer J: Cell kinetics in selection and stratification of patients for adjuvant therapy of breast carcinoma. Monogr Natl Cancer Inst 1: 25-28, 1986
66. 66. Hutson S, Cowen P, Bird C: Morphometric studies of age related changes in normal human breasts and their significance for evolution of mammary cancer. J Clin Pathol 38: 281-286, 1985
67. 67. Lippman M, Dickson R: Mechanisms of growth control in normal and malignant breast epithelium. Recent Prog Horm Res 45: 383-440, 1989
68. 68. Veronesi U, Luini A, Mariani L, et al.: Effect of menstrual phase on surgical treatment of breast cancer. Lancet 342: 1545-1547, 1994
69. 69. Stål O, Sullivan S, Wingren S, et al.: c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 31A: 2185-2190, 1995
70. 70. Silvestrini R, Veneroni S, Benini E, et al.: Expression of p53, Glutathione S-transferas-II and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer. J Natl Cancer Inst 89: 639-645, 1997
71. 71. Holland R, Leling SHJ, Mravunac M, Hendriks JHCL: Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer 56: 979-990, 1985
72. 72. Fisher E, Anderson S, Redmond C, Fisher B: Ipsilateral breast tumor recurrence and survival following lumpectomy and irradiation: Pathological findings from NSABP protocol B-06. Semin Surg Oncol 8: 161-166, 1992
73. 73. Holland R, Connolly JL, Gelman R, et al.: The presence of an extensive intraductal component following a limited excision correlates with prominent residual disease in the remainder of the breast. J Clin Oncol 8(1): 113-118, 1990
74. 74. Schnitt SJ, Abner A, Gelman R, et al.: The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy. Cancer 74: 1746-1751, 1994
75. 75. Jacobs T, Prioleau J, Stillman I, Schnitt S: Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst 88: 1054-1059, 1996